Retatrutide

Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) , in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined .

Semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) , in humans as the human relevance of semaglutide-induced rodent thyroid Ccell tumors has not been determined.

Retarutide (LY3437943) is a triple agonist peptide of glucagon receptor (GCGR) , glucose-dependent insulin-promoting peptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R) . It is a peptide composed of about 40 amino acids and contains double targets in its sequence. Retarutide inhibited human GCGR, GIPR and GLP-1R with EC50 values of 5. 79, 0. 0643 and 0. 775nM, respectively. Retarutide can be used for obesity research.

Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity.